Cardiac myosin inhibitor is safe and effective in HCM in phase 2 trial
Educational information
This video was recorded during the ESC Heart Failure 2023 in Prague, Czech Republic.
Faculty
Ahmad Masri is a cardiologist at OHSU Center for Hypertrophic Cardiomyopathy and Amyloidosis in Portland, OR, USA.
Disclosures
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
Share this page with your colleagues and friends: